ISA news

2021

December 7th — ISA to present key learnings for cancer vaccine development at the ESMO Immuno-Oncology Congress
September 14th — ISA Pharmaceuticals Receives Fast Track Designation for Lead Product ISA101b
September 8th — ISA Pharmaceuticals Commences Patient Treatment in Third Phase 2 Clinical Trial with the Combination of ISA101b and Libtayo® (cemiplimab)
July 20th — ISA, in partnership with Erasmus MC, is awarded TKI grant and expands clinical pipeline
July 13th — ISA announces successful closing of EUR 26 million funding round
May 4th — ISA Pharmaceuticals Co-authors Publication in Nature Reviews Cancer on Therapeutic Cancer Vaccines
May 3rd — ISA has relocated to brand new Biopartner 5 building
March 3rd — ISA Pharmaceuticals selects product candidate for clinical trial with first in class COVID-19 immunotherapy
February 16th — ISA features in TV program De Barometer on RTL-Z
January 26th — First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals’ Lead Immunotherapy ISA101b with Keytruda®
January 11th — ISA106 – SLP therapeutic for COVID-19

2020

October 7th — ISA Pharmaceuticals October 2020 Virtual Conference Calendar
August 6th — ISA Pharmaceuticals to present at the Virtual 6th Solebury Trout Summer 2020 Private Company Showcase
July 20th — ISA Pharmaceuticals to present at the 33rd International Papillomavirus Conference & Basic Science
July 10th — ISA Pharmaceuticals will move to BioPartner 5
July 1st — ISA Pharmaceuticals receives US Orphan-Drug Designation for ISA101b in HPV16-positive Cervical Cancer
June 23rd — ISA Pharmaceuticals to present at the Virtual European Biotech Investor Day 2020
June 22nd — Access to live broadcast ISA presentation at Virtual European Biotech Investor Day on June 25, 2020
June 17th — ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron
April 9th — Vaccine + chemo activate immune response against cervical cancer
March 30th — Vaccine-Chemo Combo Shows Promise in Treating Advanced, HPV-Associated Cervical Cancer
March 27th — ISA in the news: MedNous’ article on CervISA
March 19th — ISA Pharmaceuticals announces CervISA publication

2019

October 13th — ISA Pharmaceuticals B.V. receives EUR 20m loan from European Investment Bank
September 2nd — ISA Pharmaceuticals Strengthens its Supervisory Board with the Addition of Dr. Markwin Velders
April 30th — A One-Two Punch for HPV-16–positive Cancers?
April 18th — Video interview with ISA CSO Prof. Dr. Cornelis Melief at AACR 2019
April 3rd — CRI Speaks with 2019 AACR-CRI Lloyd J. Old Award Recipient, Dr. Cornelis ‘Kees’ Melief
March 28th — ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeting 2019
March 19th — ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Cornelis Melief Receives AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019
January 21st — ISA Pharmaceuticals Announces Start of Phase 2 Combination Trial of ISA101b and Regeneron’s Cemiplimab in Oropharyngeal Cancer
January 17th — ISA’s AMPLIVANT® publication selected as noteworthy article in the January edition of JITC Digest
January 16th — ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief to Present at Keystone Cancer Vaccines Conference

2018

2017

December 18th — ISA Pharmaceuticals and Regeneron Announce Strategic Immuno-Oncology Collaboration
October 26th — Prof. Dr. Cornelis Melief Receives Honorary Doctorate from Johannes Gutenberg University Mainz
September 21st — Interview with Dr Bonnie Glisson on the combination trial of ISA101 and Nivolumab
September 4th — Results of Phase II Combination Trial of ISA101 and Nivolumab to be Presented at ESMO 2017
May 23rd — Updated Results of Cervical Cancer Study Sponsored by ISA Pharmaceuticals to Be Presented at ASCO 2017
May 11th — ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief Honored by the Association for Cancer Immunotherapy (CIMT)
February 16th — Results of Cervical Cancer Study Sponsored by ISA Pharmaceuticals to Be Presented at ASCO-SITC

2016

2015

2014

November 27th — Publication in Nature Supports ISA Pharmaceuticals´ Synthetic Long Peptide Immunotherapeutic Approach to Treat Cancer
October 14th — ISA Pharmaceuticals Visited by the Dutch Minister of Economic Affairs
September 3rd — ISA Pharmaceuticals Appoints Hendrik-Jan Laseur as Member of the Supervisory Board
July 7th — ISA Pharmaceuticals Appoints Ronald Loggers as Chief Executive Officer
April 10th — New Clinical Data Demonstrate Strong Synergy between Cancer Vaccine ISA101 and Chemotherapy
March 27th — New Clinical Data on Cancer Vaccine ISA101 to Be Presented at the AACR Annual Meeting 2014
February 24th — ISA Pharmaceuticals Strengthens Patent Protection for its Lead Product ISA101

2013

December 20th — Radiouitzending met Kees Melief (CSO ISA Pharmaceuticals) over Kankerimmunotherapie
October 29th — ISA Pharmaceuticals Initiates Phase I/II Clinical Trial With ISA101 in Women with Cervical Cancer
October 15th — ISA Pharmaceuticals Establishes Advisory Board
September 30th — ISA Pharmaceuticals Presents Novel Data at the European Cancer Congress 2013: Strong Synergies Between Cancer Vaccine ISA101 and Chemotherapy
September 16th — ISA Pharmaceuticals Initiates Phase I/II Clinical Trial of ISA101 in Patients with Anal Intraepithelial Neoplasia (AIN)
September 4th — Publication Demonstrates Superior Activity of ISA Pharmaceuticals´ SLP® Vaccines Compared to Whole Protein Vaccines
July 15th — Three Peer-Reviewed Papers by ISA Pharmaceuticals Introduce Strategies to Improve Immunotherapy Against Cancer
July 8th — ISA Pharmaceuticals Strengthens Management Team
April 9th — Novel AMPLIVANT™ Technology Introduced at AACR Annual Meeting 2013
April 2nd — Prof. Cornelis Melief to Present Novel AMPLIVANT™ Platform at AACR Annual Meeting 2013
January 7th — ISA Pharmaceuticals Secures EUR 8 Million Funding

2011